Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤Tiffany Howard named Executive Vice President, Commercial – Retina
- ➤Inducement awards cover 200,000 stock options and 65,000 restricted stock units
- ➤Stock options priced at $6.01 per share with a ten-year term
- ➤AXPAXLI remains in Phase 3 trials for wet AMD and diabetic retinal disease
BEDFORD, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Tiffany Howard, the Company’s new Executive Vice President, Commercial – Retina. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards were granted effective as of November 16, 2026, and consist of a non-statutory stock option award to purchase up to 200,000 shares of Ocular’s common stock and a restricted stock unit award representing the right to receive 65,000 shares of Ocular’s common stock. The stock option award has an exercise price of $6.01 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. The stock option award has a ten-year term and vests over four years, with 25% of the original number of shares subject to the award vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The restricted stock unit award vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates.
Get started
Create a free account to read the full story.
